kobayashi.co.jpCrawled Oct 15, 2026
KOBAYASHI Pharmaceutical's corporate philosophy including its identity statement is available here.
In the Corporate Profile section, a Message from the CEO and information on KOBAYASHI Pharmaceutical's corporate philosophy, products and services, and history are available.
The page provides contact information for Kobayashi Pharmaceutical Group, with forms for general and investor relations inquiries and annual report requests.
Kobayashi Pharmaceutical Co., Ltd. provides information on pharmaceuticals, quasi-drugs, skincare products, Kampo medicine, air fresheners and deodorizers, and hygiene products. The site also features an online store and offers, including product monitor opportunities and giveaways.
Kobayashi Pharmaceutical Co., Ltd. provides information on pharmaceuticals, quasi-drugs, skincare products, Kampo medicine, air fresheners and deodorizers, and hygiene products. The site also features an online store and offers, including product monitor opportunities and giveaways.
The global website presents corporate information and the company's mission.
Kobayashi Pharmaceutical faces a potential buyout valued at over ¥500 billion from private equity investors. The company remains under scrutiny following a supplement contamination scandal linked to red-yeast rice products and suspected fatalities. The proposed deal reflects investor interest amid regulatory and reputational challenges.
Sep 2026The Japan TimesNews article
Private equity firms CVC and NSSK are in advanced talks to acquire Kobayashi Pharmaceuticals in a deal potentially exceeding ¥500 billion. The discussions follow a red yeast supplement scandal involving product recalls and a ¥12.7 billion financial charge for the company. The buyout may include participation from Kobayashi’s family stakeholders.
Sep 2026Briefs FinanceNews article
Japan’s health ministry will require businesses selling dietary supplements to report health issues linked to their products. The new rule aims to enhance consumer safety by tracking adverse reactions. The expert panel finalized the proposal after discussions on regulatory oversight.
Jul 2026The Japan TimesNews article
Kobayashi Pharmaceutical reports **33.7 billion yen in net sales** for Q1 of its fiscal year ending December 31, 2026, marking a **3.2% year-over-year increase**. The company provides consolidated financial results under Japanese GAAP, reflecting its core pharmaceutical business performance. No further operational details or segment-specific metrics are disclosed in the brief summary.
May 2026BigGo FinanceNews article
